This prospective study aimed to investigate the influence of pretransplant serum ferritin levels on the outcomes of allogeneic hematopoietic SCT (HSCT). In total, 190 patients with acute leukemia or myelodysplastic syndrome were consecutively enrolled. The patients were divided into two groups: low-ferritin group (o 1000 ng/mL) and high-ferritin group (⩾1000 ng/mL). The primary end point was the cumulative incidence of infection within 100 days after HSCT, which was similar between the two groups: bloodstream infection, 35 vs 38%, P = 0.65; bacterial infection, 44 vs 41%, P = 0.68; and fungal infection, 6 vs 8%, P = 0.71. The 1-year adjusted probability of OS of the high-ferritin group was significantly lower than that of the low-ferritin group (76 vs 63%, P = 0.017). Using receiver operating characteristic curve, the threshold of pretransplant serum ferritin levels for bloodstream infection was 1400 ng/mL; the threshold for OS, EFS and non-relapse mortality was 1349 ng/mL. In conclusion, pretransplant serum ferritin levels of ⩾ 1000 ng/mL did not influence the incidence of infection but adversely affected OS after HSCT. A higher threshold of pretransplant serum ferritin levels may predict HSCT outcomes.
INTRODUCTION
Allogeneic hematopoietic SCT (HSCT) is a curative treatment option for patients with hematologic malignancies. However, morbidities and mortalities, such as organ failure caused by pretransplant conditioning, infection and GVHD, have been major limitations for successful treatment. Recent studies have demonstrated that pretransplant iron overload, defined as elevated serum ferritin levels, is associated with worse OS, disease-free survival and non-relapse mortality (NRM) and with an increased risk of infection in patients undergoing allogeneic HSCT. [1] [2] [3] [4] [5] [6] [7] [8] [9] Liver dysfunction caused by iron overload 10 and neutrophil dysfunction with an increase in non-transferrin-bound iron levels 11, 12 may have a negative impact on HSCT outcomes. However, most previous studies involved retrospective analyses of patients with heterogeneous diseases. To clarify the correlation between pretransplant serum ferritin levels and transplant outcomes including infection, NRM and survival, we conducted a multicenter prospective cohort study in patients with acute leukemia or myelodysplastic syndrome undergoing allogeneic HSCT.
PATIENTS AND METHODS

Study design and definitions
This study was a prospective multicenter cohort trial of the Kanto Study Group for Cell Therapy. The study consecutively enrolled patients between March 2010 and December 2012. Eligible patients were aged ⩾ 20 years with acute leukemia or myelodysplastic syndrome. Patients who had previously undergone allogeneic or autologous HSCT were excluded. Written informed consent was obtained from all patients before entry in the study. The institutional review board of each participating center reviewed and approved the study. The trial was conducted in accordance with the Declaration of Helsinki and was registered as UMIN000003460.
The primary end point was the influence of pretransplant serum ferritin levels on the cumulative incidence of infectious disease within 100 days after HSCT. The secondary end points were as follows: cumulative incidence of neutrophil recovery, acute GVHD and NRM within 100 days after HSCT; cumulative incidence of chronic GVHD, NRM and relapse within 1 year after HSCT; and probability of OS and EFS at 1 year after HSCT. Conditioning regimen, stem cell source, GVHD prophylaxis and prevention of infectious disease were performed according to the protocol at each center.
Serum ferritin levels within 30 days before transplantation were measured in all patients who did not have infection. Patients were divided
The intensity of conditioning regimen was defined as previously described. 13, 14 Acute leukemia in the first or second CR, refractory anemia with or without ringed sideroblasts and refractory cytopenia with multilineage dysplasia for myelodysplastic syndrome were defined as a standard risk, whereas all other states were defined as high risk. Invasive fungal infections were diagnosed and classified according to the EORTC/ MSG criteria. 15 Bloodstream infection was defined as blood culture positive for bacteria or fungus. Neutrophil recovery was defined as an ANC of ⩾ 500/μL for the first 3 consecutive days. Acute GVHD was evaluated on the basis of standard criteria. 16 Chronic GVHD was defined on the basis of standard classification. Patients who did not obtain CR after HSCT were defined as those who relapsed the day after HSCT. NRM was defined as death without relapse.
Statistical analysis
The cumulative incidence of bloodstream infection within 100 days after HSCT was expected to be 21% in the low-ferritin group and 42% in the high-ferritin group. 9 A statistical power of 80% and a 5% probability of type I error were computed at 74 patients per group, with a 1:1 distribution of both groups. The final sample size was increased to 200 patients to account for the imbalance in the number of patients between both groups. As exploratory analysis, we used a conventional receiver-operating characteristic (ROC) curve to identify the threshold of pretransplant serum ferritin levels for transplant outcomes.
Demographic factors and disease characteristics were compared between the two groups using Fisher's exact test for categorical data and Mann-Whitney U-test for continuous variables. Unadjusted OS and EFS were estimated using the Kaplan-Meier method. Cox proportional hazards regression model was used for multivariate analyses of OS and EFS. Gray's test was employed for comparison of the cumulative incidence curves for infection, relapse, NRM, neutrophil recovery and GVHD. 17 NRM and relapse were the competing events for each other. Death without an event was the competing event for infection, neutrophil recovery and GVHD. Fine and Gray's proportional hazard regression model was employed for multivariate analyses with competing risks. 18 Multivariate analyses to compare the effect of pretransplant serum ferritin levels on transplant outcomes were performed with consideration of other significant clinical variables. Final models were built from significant variables (Po 0.2) in univariate analysis; each variable was then deleted from the model in a stepwise manner when it was not statistically significant (P40.05). Pretransplant serum ferritin (high-ferritin group vs low-ferritin group) was added in the final model. Adjusted comparison of the effect of pretransplant serum ferritin levels on EFS and OS was performed with the final multivariate model. All tests were two-sided, and Po0.05 was considered to indicate statistical significance. Analyses were performed with EZR version 1.25 (Saitama Medical Center, Jichi Medical University), 19 which is a graphical user interface for R version 3.0.2 (R Development Core Team, Vienna, Austria).
RESULTS
Patient and transplantation characteristics
The patient and transplantation characteristics are shown in Table 1 . A total of 221 patients were enrolled. Of these, 31 patients were excluded: 13 who were enrolled after HSCT, 14 who had infection at transplantation, 1 who had CML, 1 who died before HSCT and 2 with missing data. Finally, 190 patients were evaluated in this analysis. Of these, 111 patients were included in the lowferritin group and 79 patients were included in the high-ferritin group. The low-ferritin group had a significant preponderance of female patients compared with the high-ferritin group (P = 0.003).
The median duration of follow-up for the surviving patients was 19.6 months (range: 1.3-30.1 months) in the low-ferritin group and 19.9 months (range: 2.4-31.9 months) in the highferritin group.
Infection
The cumulative incidence of bloodstream, bacterial and fungal infections in the low-ferritin group was comparable to that in the high-ferritin group: bloodstream infection, 35% (26-44%) vs 38% (27-49%), P = 0.65; bacterial infection, 44% (35-53%) vs 41% (30-51%), P = 0.68; and fungal infection, 6% (3-12%) vs 8% Table 2 ).
Neutrophil recovery
The median time from transplantation to neutrophil recovery was 19 days (range: 11-38 days) in the low-ferritin group and 20 days (range: 1-38 days) in the high-ferritin group (P = 0.07). Neutrophil recovery was faster in recipients who underwent transplantation at a standard risk than in those with high-risk disease (P o0.001).
On multivariate analysis, neutrophil recovery was slower in the high-ferritin group than in the low-ferritin group (HR: 0.73, 95% CI: 0.53-0.99, P = 0.045; Table 2 ).
Acute and chronic GVHD The cumulative incidence of grade II-IV acute GVHD within 100 days after transplantation was similar in the low-ferritin group and high-ferritin group (41% (31-50%) vs 36% (25-46%), P = 0.42; Number at risk Ferritin < 1000 Ferritin ≥ 1000 c Figure 1 . Cumulative incidence of bacterial, fungal and bloodstream infections within 100 days after transplantation according to pretransplant serum ferritin levels. (a) The cumulative incidence of bloodstream infection was 35% in patients with low pretransplant serum ferritin levels and 36% in patients with high pretransplant serum ferritin levels (P = 0.65). (b) The cumulative incidence of bacterial infection was 44% in patients with low pretransplant serum ferritin levels ( o 1000 ng/mL) and 41% in patients with high pretransplant serum ferritin levels (⩾1000 ng/mL) (P = 0.68). (c) The cumulative incidence of fungal infection was 6% in patients with low pretransplant serum ferritin levels and 8% in patients with high pretransplant serum ferritin levels (P = 0.71). Figure 2a) . The high-ferritin group had a similar risk of grade II-IV acute GVHD compared with the low-ferritin group on multivariate analysis (HR: 0.88, 95% CI: 0.52-1.49, P = 0.63; Table 2 ). Reduced-intensity conditioning had a significantly lower risk than myeloablative conditioning (HR: 0.32, 95% CI: 0.15-0.69, P = 0.004).
The cumulative incidence of chronic GVHD at 1 year after transplantation was significantly lower in the low-ferritin group than in the high-ferritin group (36% (26-46%) vs 55% (42-67%), P = 0.027; Figure 2b ). On multivariate analysis, the high-ferritin group had a significantly higher risk of chronic GVHD (HR: 1.74, 95% CI: 1.07-2.83, P = 0.022; Table 2 ). Both groups were similar in terms of distribution of sites involved with chronic GVHD, except the gut (Table 3) .
Relapse
The cumulative incidence of relapse at 1 year in the low-ferritin group was comparable to that in the high-ferritin group (25% (17-33%) vs 27% (17-37%), P = 0.67; Figure 3a) . On multivariate analysis, both groups had a similar risk of relapse (HR: 1.10, 95% CI: 0.64-1.89, P = 0.74; Table 2 ). Only high-risk disease at transplantation was a significant risk factor for relapse (HR: 2.73, 95% CI: 1.60-4.66, P o 0.001).
Non-relapse mortality The cumulative incidence of NRM within 100 days and 1 year in the low-ferritin group was higher, but not statistically significant, than that in the high-ferritin group (100 days: 5% (2-11%) vs 8% (3-15%); 1 year: 14% (8-21%) vs 20% (12-30%), P = 0.1; Figure 3b ). High pretransplant serum ferritin levels did not have a significant effect on NRM on multivariate analysis (HR: 1.60, 95% CI 0.83-3.09, P = 0.16; Table 2 ).
Survival
The 1-year unadjusted and adjusted probabilities of OS in the lowferritin group were significantly higher than those in the highferritin group (unadjusted OS: 73% (63-80%) vs 56% (45-66%), P = 0.006; adjusted OS: 76% (68-84%) vs 63% (52-75%), P = 0.017; Figure 3c ). However, the unadjusted and adjusted probabilities of EFS at 1 year after HSCT in the low-ferritin group were not statistically different compared with those in the high-ferritin group (unadjusted EFS: 62% (52-70%) vs 53% (42-63%), P = 0.1; adjusted EFS: 63% (54-73%) vs 58% (48-71%), P = 0.28; Figure 3d ). The discrepancy in the effect of pretransplant serum ferritin levels on OS and EFS was caused by the difference in survival after relapse. At 1 year after relapse, OS was 30% in the lowferritin group and 16% in the high-ferritin group (P = 0.036; Number at risk Ferritin < 1000 Ferritin ≥ 1000
Ferritin < 1000
Ferritin ≥ 1000 a b Figure 2 . Cumulative incidence of grade II-IV acute GVHD and extensive type of chronic GVHD according to pretransplant serum ferritin levels. (a) The cumulative incidence of grade II-IV acute GVHD within 100 days after transplantation was 41% in patients with low pretransplant serum ferritin levels ( o1000 ng/mL) and 36% in patients with high pretransplant serum ferritin levels (⩾1000 ng/mL) (P = 0.42). (b) The cumulative incidence of extensive chronic GVHD within 1 year after transplantation was 24% in patients with low pretransplant serum ferritin levels ( o1000 ng/mL) and 40% in patients with high pretransplant serum ferritin levels (⩾1000 ng/mL) (P = 0.045).
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Supplementary Figure 1) . According to multivariate analysis, the low-ferritin group had significantly better OS but not EFS (OS: HR: 1.79, 95% CI: 1.11-2.89, P = 0.017; EFS: HR: 1.27, 95% CI: 0.82-1.97, P = 0.28; Ferritin < 1000
Ferritin ≥ 1000 a b c d Figure 3 . Cumulative incidence of relapse, non-relapse mortality (NRM) and adjusted probabilities of OS and EFS according to pretransplant serum ferritin levels. (a) The cumulative incidence of relapse within 1 year after transplantation was 25% in patients with low pretransplant serum ferritin levels ( o1000 ng/mL) and 27% in patients with high pretransplant serum ferritin levels (⩾1000 ng/mL) (P = 0.67). (b) The cumulative incidence of NRM within 1 year after transplantation was 14% in patients with low pretransplant serum ferritin levels and 20% in patients with high pretransplant serum ferritin levels (P = 0.1). (c) Adjusted probabilities of 1-year OS was 76% in patients with low pretransplant serum ferritin levels and 63% in patients with high pretransplant serum ferritin levels (P = 0.017). (d) Adjusted probabilities of 1-year EFS was 63% in patients with low pretransplant serum ferritin levels and 58% in patients with high pretransplant serum ferritin levels (P = 0.28).
Causes of death
The causes of death are shown in Table 4 . More than half of the causes of death within 100 days after transplantation were NRM in both groups, whereas the main cause of late death after transplantation was relapse and progression of the primary disease. The distribution of causes of death was not statistically different in both groups.
ROC curve to identify an appropriate threshold of pretransplant serum ferritin levels According to the ROC curve, the threshold of pretransplant serum ferritin levels that gave the maximal sensitivity and specificity for bloodstream infection was 1400 ng/mL. The cumulative incidence of bloodstream infection in patients with low pretransplant serum ferritin levels ( o1400 ng/mL) was lower than that in those with high pretransplant serum ferritin levels (⩾1400 ng/mL) (32% (25%-40%) vs 48% (33-61%), P = 0.054; Supplementary Figure  2A) . No appropriate threshold was identified for bacterial infection and fungal infection by the ROC curve. The appropriate serum ferritin threshold for both OS and EFS was 1349 ng/mL. The unadjusted probability of OS in patients with low pretransplant serum ferritin (o 1349 ng/mL) was significantly higher than that in patients with high pretransplant serum ferritin (⩾1349 ng/mL) (74% (65-80%) vs 47% (33-60%), P o0.001; Supplementary Figure  2B ). The unadjusted probability of EFS showed the same trend using serum ferritin levels of 1349 ng/mL as the cutoff (64% (55-71%) vs 44% (31-57%), P = 0.003; Supplementary Figure 2C) . The cumulative incidence of NRM was significantly lower in patients with low pretransplant serum ferritin levels (cutoff at 1349 ng/mL) than in those with high pretransplant serum ferritin levels (13% (8-19%) vs 26% (15-39%), P = 0.01; Supplementary Figure 2D ). On multivariate analysis, pretransplant serum ferritin levels of ⩾ 1349 ng/mL was a significant negative predictor of OS (HR: 2.12, 95% CI: 1.31-3.44, P = 0.002) and NRM (HR: 2.00, 95% CI: 1.01-3.97, P = 0.048). However, pretransplant serum ferritin levels of ⩾ 1349 ng/mL had a non-significant negative impact on EFS (HR: 1.53, 95% CI: 0.98-2.39, P = 0.064).
DISCUSSION
The objective of the current study was to determine the influence of pretransplant serum ferritin levels on transplant outcomes including infection, NRM, GVHD and survival. We and other groups have previously reported that patients with high serum ferritin levels before transplantation develop post-transplant infection more frequently than those with low serum ferritin levels. 1, 7, 9 An extremely low level of free ionic iron (~10 − 18 M) in tissue fluids and plasma is associated with natural resistance to bacterial invasion. 11 Iron overload causes transferrin saturation, resulting in an increase in non-transferrin-bound iron levels. However, in the present study, the incidence of bloodstream, bacterial and fungal infections was similar regardless of the pre-HSCT serum ferritin levels. This may have been due to a rapid increase in serum transferrin saturation to~99% after initiation of myeloablative conditioning regimen and due to the appearance of nontransferrin-bound iron during transplantation in most of patients. 20 The two groups in our cohort differed by only 1 day in the median interval from transplantation to neutrophil recovery; however, a high pretransplant serum ferritin level was a significant negative predictor of neutrophil recovery on multivariate analysis. Iron chelation therapy improves hematopoiesis, suggesting that a high serum ferritin level was associated with disorders of hematopoiesis.
The impact of pre-HSCT serum ferritin levels on chronic GVHD in previous studies varied. 6, [21] [22] [23] [24] Mahindra et al. 21 demonstrated that high serum ferritin levels (41910 ng/mL) reduced the risk of chronic GVHD in patients receiving myeloablative conditioning; this may be due to a reduced immune response with high serum ferritin levels. Sakamoto et al. 23 described a high incidence of chronic GVHD in patients with low pretransplant serum ferritin levels ( o880 ng/mL). Lim et al. 22 reported that pretransplant serum ferritin levels did not influence the cumulative incidence of chronic GVHD in patients receiving reduced intensity conditioning. Our findings suggest that high serum ferritin levels before transplantation increase the risk of chronic GVHD. The reason for this discrepancy remains unclear. The more frequent incidence of chronic GVHD in patients with high ferritin levels may be due, in part, to iron overload that is associated with increased susceptibility to organ damage.
The main cause of death was relapse or progression of primary disease in both groups. Our data suggest that pretransplant serum ferritin levels did not influence the relapse rate after HSCT. In terms of the cumulative incidence of NRM at 1 year, the absolute difference between high and low (cutoff at 1000 ng/mL) pretransplant serum ferritin levels was only 6%. High pretransplant serum ferritin levels were partly caused by iron overload, resulting in organ damage. Because each cause of NRM, such as infection, GVHD and IP, included small number of patients in both groups, we could not determine whether each distinct complication was increased in the high-ferritin group.
Our study showed that OS at 1 year after HSCT in patients with high pretransplant serum ferritin levels was significantly inferior to that in patients with low pretransplant serum ferritin levels. As described above, this was mainly caused by a difference in the incidence of NRM. We and other groups have previously demonstrated that high serum ferritin levels before HSCT may reduce OS and EFS after HSCT. [1] [2] [3] [4] [5] [6] [7] [8] [21] [22] [23] [24] To the best of our knowledge, the present study is the first to confirm these findings using a large prospective cohort.
Analysis using the ROC curve enabled us to determine the appropriate threshold of pretransplant serum ferritin levels for HSCT outcomes. The cutoff value of ferritin levels was 41000 ng/mL for bloodstream infection, NRM, EFS and OS. Serum ferritin levels increase not only from iron overload but also from inflammation; hence, the appropriate cutoff value may vary depending on the clinical condition when serum ferritin levels are measured. In our patients, pretransplant serum ferritin levels were measured in the absence of any infectious disease; thus, the high serum ferritin values obtained were mainly a result of iron overload, suggesting that moderate, rather than mild, iron overload has a negative impact on HSCT outcomes.
In conclusion, in the present study, pre-HSCT serum ferritin cutoff levels of 1000 ng/mL did not influence the incidence of Prospective study of hyperferritinemia in HSCT M Tanaka et al infection; however, high serum ferritin levels before HSCT had an adverse effect on the probability of OS. For bloodstream infection and EFS, the appropriate threshold of pretransplant serum ferritin levels may be 41000 ng/mL. To reduce the incidence of NRM and to improve OS in patients with high pretransplant serum ferritin levels, we will conduct a trial to investigate an appropriate iron chelation therapy with deferasirox.
